Type 2 Diabetes Clinical Trial
Official title:
Examining the Effects of Consuming a Diet Comprising of Milk Fat on Metabolic Health Markers
This study investigates the effects of bioactive fatty acids in full fat dairy (whole yogurt), on insulin action, calorie needs, blood lipids, immune function, and body composition in normal and overweight male and female volunteers.
Saturated fats impair the action of insulin leading to abnormally high blood sugar levels
that are characteristic of diabetes. Since milk fat is high in saturated fat, some experts
advise against whole dairy products (e.g., milk and yogurt). However, bioactive fats, such
as those which occur in milk fat, may be beneficial in the prevention of diabetes.
Current data provide no compelling evidence that a moderate intake of saturated fat from
milk fat increases the risk of diabetes. Milk fat contains a unique variety of bioactive
fats, which may be beneficial and may counterbalance the potential negative effects of
saturated fat.
The investigators hypothesize that milk fat has favorable effects on metabolic risk markers
associated with the metabolic syndrome. Therefore, this study tests the hypothesis that
milk-fat intake will:
(i) result in improved insulin sensitivity,
(ii) favorably alter postprandial lipid metabolism, and
(iii) result in lower circulating concentrations of pro-inflammatory markers.
This study recruits 20-24 (total) female and male subjects in a blinded, randomized,
crossover design consisting of two experimental diets (3 weeks each arm) based on a
DASH-like diet (Dietary Approaches to Stop Hypertension diet) with % Energy (E%): 55 E% of
carbohydrate, 15 E% of protein, and 30 E% of fat (9 E% saturated fatty acids (SFA), 15 E% of
monounsaturated fatty acids (MUFA), and 6 E% of polyunsaturated fatty acids (PUFA)). One
experimental arm contains milk fat and the other diet contains a control fat.
A washout period represents an average US diet (48 E% of carbohydrate, 15 E% of protein and
37 E% of fat, kcal (16 E% of SFA, 14 E% of MUFA, and 7 E% of PUFA) is used to establish a
level of normalization of the fatty acid intake among the subjects and to standardize the
subject's physiologic state before each experimental diet.
The two experimental diets are constructed to provide three servings of dairy in the form of
either 1) regular whole (full-fat, 3.25%) yogurt or 2) fat-free yogurt supplemented with a
control fat. The diets are identical in terms of menus, macro- and micronutrients, and fatty
acid class composition (E%) with the exception of individual bioactive fatty acids, allowing
for the comparison of the bioactive milk fatty acids to non-milk fatty acids.
At the end of each period (initial washout period and each experimental diet) a frequently
sampled intravenous glucose tolerance test is performed, blood is taken for fasting lipids
(including lipoprotein profile), serum phospholipid fatty acid profiles, and inflammatory
markers, and stool is sampled to examine the fecal microbiota composition.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |